The global cancer biomarkers market size is forecast to reach USD 48.20 billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers.As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR,KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals &Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026.
Report Highlights
The report offers a comprehensive overview of the market and its prime growth trajectories, such as drivers, restraints, challenges, and opportunities. It throws light on recent oncology biomarker market trends, key industry developments, and other interesting insights. The report emphasizes on the table of segmentation based on factors such as cancer type, biomarker type, end user, and geography. The report discusses the list of players operating in the market and the prime strategies adopted by them to gain a competitive edge in the market. For more information on the report, log on to the company website.
The COVID-19 pandemic has caused huge losses for several companies by halting their manufacturing processes. The governments of various companies are persistently striving to prevent the transmission of coronavirus by promoting social distancing and sanitization measures. Our reports would help you in gaining more insights into the effects of COVID-19 on every market.
The Cancer Biomarkers Market report offers an in-depth analysis of the Cancer Biomarkers industry and the demand drivers by highlighting information on several aspects of the market. Prudent Markets addresses all these aspects and provides the latest scoop and detailed eye-opening study on all major & emerging business segments. In addition to this, the report sheds light on the industry developments by key players, which are contributing to the expansion of this industry. The development scope, feasibility study, Cancer Biomarkers market concentration, and maturity analysis is elaborated in this report.
Information given in the research report pertains to different technological advancements introduced in recent years, which allows for a meticulous analysis of the industry and offers a more comprehensive understanding to the readers.
The outbreak of covid-19 in the global market has made companies uncertain about their future scenario as the prolonged lock-down finds a serious economic slump. The latest survey on COVID-19 Outbreak-Global Cancer Biomarkers Market is conducted to provide hidden gems performance analysis. Essential growth factors and study of Basis points [BPS] have been discussed in the following report. Research Report explains a detailed overview of market dynamics, segmentation, product portfolio, business plans, and the latest development in the industry.
Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/cancer-biomarkers-market-100630
Market Drivers
Rise in Prevalence of Cancer Worldwide to Augment Growth
The increasing prevalence of cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various cancer types. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high cancer biomarkers market revenue in the coming years.
On the flip side, the market may face challenges in terms of reimbursement policies supported by the governments. This is further attributed to the high cost of treatment for cancer,especially in developing nations. Nevertheless, government support in spreading awareness about cancer, and the availability of treatment options for the same are likely to create lucrative growth opportunities for the market in the forthcoming years.
Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.
It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for Cancer Biomarkers market to figure out and study the market’s needs, market size, and competition.
Regional Segmentation:
North America to Emerge Dominant Owing to Higher Adoption of Next-Generation Sequencing
From a geographical perspective, the global cancer biomarker market is widespread into the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Each of these regions is further categorized into nations. Among these, North America earned USD 6.88 billion in 2018 and emerged dominant owing to the high adoption personalized medicine. Europe ranks second in the market with a rising number of research studies for using biomarkers in development and discovery.
Furthermore, the market in the Asia Pacific is expected to contribute significant oncology biomarker market share on account of rising in investments for research and development of biomarkers. This, coupled with increasing support from government and private bodies for the drug development process and patient stratification.
Competitive Landscape:
Substantial Investment in Research and Development of Novel Therapeutics to Escalate Market Competition
Major companies in the Global Cancer Biomarkers Market are increasingly focusing on research and development activities to create new and innovative products to stay ahead of the competition. Staying on top of market trends & drivers is crucial for decision-makers to hold this emerging opportunity. The study provides information on market trends and development, drivers, capacities, technologies, and the changing investment structure of the Healthcare Industry.
The global cancer biomarker market is semi-consolidated in nature. Notable players operating in the market are engaging in strategic collaborations such as mergers and acquisitions, joint ventures, company collaborations, and others to gain an edge in the market competition. Apart from this, players are investing massive amounts into research and development of novel therapeutic solutions for various cancer types. Thermo Fisher Scientific, Inc., Abbott, and F. Hoffmann-La Roche Ltd. are currently holding dominant cancer biomarker market shares.
This report focuses on Cancer Biomarkers Global Market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Regional analysis is another highly comprehensive part of the research and analysis study of the global market presented in the report. This section sheds light on the sales growth of different regional and country-level markets. For the historical and forecast period to 2026, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.
Cancer Biomarkers Market Highlights of the Report:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.
- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market
Enquire before buying:
https://www.fortunebusinessinsights.com/enquiry/queries/cancer-biomarkers-market-100630
List of Key Cancer Biomarker Market Manufacturers:
- Myriad RBM
- Abbott
- Hoffmann-La Roche Ltd.
- BioVision Inc.
- Thermo Fisher Scientific
- R&D System
- Bio-Rad Laboratories, Inc.
- Sino Biological Inc.
- CENTOGENE N.V.
- Sino Biological Inc.
- Axon Medchem
Significant Industry Developments of Cancer Biomarkers Market Include:
March 2018 –Oncotype DX AR-V7 nucleus detect test, a predictive and prognostics biomarker was launched by Genomic Health Inc. The test helps in therapeutic decisions among patients who suffer from metastatic castration-resistant prostate cancer (mCRPC) by recognizing a connected variant of the androgen receptor protein namely AR-V7 situated in the nucleus of the circulating tumor cells (CTCs).
November 2018 – A collaborative agreement was signed between AstraZeneca and Biocartis Group NV to obtain molecular diagnostics biomarker for quick results in lung cancer patients across the European region.
Table of Contents:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence/ Incidence, by Cancer Type, by Key Regional/ Countries
- New Product Launches, by Key Market Players
- Pipeline Analysis, Cancer Biomarkers
- Key industry Developments – Mergers, Acquisitions and Partnerships
- Global Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Market Analysis, Insights and Forecast – By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
- Others
- Market Analysis, Insights and Forecast – By End User
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Market Analysis, Insights and Forecast – By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
- Others
- Market Analysis, Insights and Forecast – By End User
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
- Market Analysis, Insights and Forecast – By Country/ Sub-region
- S.
- Canada
- Europe Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Market Analysis, Insights and Forecast – By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
- Others
- Market Analysis, Insights and Forecast – By End User
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
- Market Analysis, Insights and Forecast – By Country/ Sub-region
- K.
- Germany
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Cancer Type
- Lung Cancer Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Market Analysis, Insights and Forecast – By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
- Others
- Market Analysis, Insights and Forecast – By End User
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
- Market Analysis, Insights and Forecast – By Country/ Sub-region
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Market Analysis, Insights and Forecast – By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
- Others
- Market Analysis, Insights and Forecast – By End User
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
- Market Analysis, Insights and Forecast – By Country/ Sub-region
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Market Analysis, Insights and Forecast – By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
- Others
- Market Analysis, Insights and Forecast – By End User
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
- Market Analysis, Insights and Forecast – By Country/ Sub-region
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- Competitive Analysis
- Key Industry Developments
- Global Market Share Analysis (2018)
- Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- Hoffmann-La Roche Ltd.
- Abbott
- CENTOGENE N.V.
- Bio-Rad Laboratories, Inc.
- CENTOGENE N.V.
- Axon Medchem
- Sino Biological Inc.
- R&D System
- BioVision Inc.
- Myriad RBM
- Other Prominent Players
- Strategic Recommendation
List of Tables
Table 1: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2015–2026
Table 2: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2015–2026
Table 3: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2015–2026
Table 4: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Region, 2015-2026
Table 5: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2015-2026
Table 6: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2015-2026
Table 7: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2015-2026
Table 8: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country, 2015-2026
Table 9: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2015-2026
Table 10: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2015-2026
Table 11: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2015-2026
Table 12: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2015-2026
Table 13: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2015-2026
Table 14: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2015-2026
Table 15: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2015-2026
Table 16: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2015-2026
Table 17: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2015-2026
Table 18: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2015-2026
Table 19: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2015-2026
Table 20: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2015-2026
Table 21: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2015-2026
Table 22: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2015-2026
Table 23: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2015-2026
Table 24: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2015-2026
List of Figures
Figure 1: Global Cancer Biomarkers Market Revenue Breakdown (US$ Mn, %) by Region, 2018 & 2026
Figure 2: Global Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2018 & 2026
Figure 3: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer, 2015-2026
Figure 4: Global Cancer Biomarkers Market Forecast (US$ Mn), by Cancer, 2015-2026
Figure 5: Global Cancer Biomarkers Market Forecast (US$ Mn), by Colorectal Cancer, 2015-2026
Figure 6: Global Cancer Biomarkers Market Forecast (US$ Mn), by Prostate Cancer, 2015-2026
Figure 7: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2015-2026
Figure 8: Global Cancer Biomarkers Market Value Share (%), by Biomarker Type 2018 & 2026
Figure 9: Global Cancer Biomarkers Market Forecast (US$ Mn), by PSA, 2015-2026
Figure 10: Global Cancer Biomarkers Market Forecast (US$ Mn), by HER-2, 2015-2026
Figure 11: Global Cancer Biomarkers Market Forecast (US$ Mn), by EGFR, 2015-2026
Figure 12: Global Cancer Biomarkers Market Forecast (US$ Mn), by KRAS 2015-2026
Figure 13: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2015-2026
Figure 14: Global Cancer Biomarkers Market Value Share (%), by End User, 2018 & 2026
Figure 15: Global Cancer Biomarkers Market Forecast (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2015-2026
Figure 16: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer & Research Laboratories, 2015-2026
Figure 17: Global Cancer Biomarkers Market Forecast (US$ Mn), by Hospitals & Speciality Clinics, 2015-2026
Figure 18: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2015-2026
Figure 19: Global Cancer Biomarkers Market Value (US$ Mn), by Region, 2018 & 2026
Figure 20: North America Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2018 & 2026
Figure 21: North America Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2018
Figure 22: North America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2018 & 2026
Figure 23: North America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2018
Figure 24: North America Cancer Biomarkers Market Value (US$ Mn), by End User, 2018 & 2026
Figure 25: North America Cancer Biomarkers Market Value Share (%), by End User, 2018
Figure 26: North America Cancer Biomarkers Market Value (US$ Mn), By Country, 2018 & 2026
Figure 27: North America Cancer Biomarkers Market Value Share (%), By Country, 2018
Figure 28: Europe Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2018 & 2026
Figure 29: Europe Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2018
Figure 30: Europe Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2018 & 2026
Figure 31: Europe Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2018
Figure 32: Europe Cancer Biomarkers Market Value (US$ Mn), by End User, 2018 & 2026
Figure 33: Europe Cancer Biomarkers Market Value Share (%), by End User, 2018
Figure 34: Europe Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2018 & 2026
Figure 35: Europe Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2018
Figure 36: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2018 & 2026
Figure 37: Asia Pacific Cancer Biomarkers Market Value Share (%), by Cancer Type, 2018
Figure 38: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2018 & 2026
Figure 39: Asia Pacific Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2018
Figure 40: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by End User, 2018 & 2026
Figure 41: Asia Pacific Cancer Biomarkers Market Value Share (%), by End User, 2018
Figure 42: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2018 & 2026
Figure 43: Asia Pacific Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2018
Figure 44: Latin America Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2018 & 2026
Figure 45: Latin America Cancer Biomarkers Market Value Share (%), by Cancer Type, 2018
Figure 46: Latin America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2018 & 2026
Figure 47: Latin America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2018
Figure 48: Latin America Cancer Biomarkers Market Value (US$ Mn), by End User, 2018 & 2026
Figure 49: Latin America Cancer Biomarkers Market Value Share (%), by End User, 2018
Figure 50: Latin America Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2018 & 2026
Figure 51: Latin America Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2018
Figure 52: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2018 & 2026
Figure 53: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Cancer Type, 2018
Figure 54: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2018 & 2026
Figure 55: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2018
Figure 56: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by End User, 2018 & 2026
Figure 57: Middle East & Africa Cancer Biomarkers Market Value Share (%), by End User, 2018
Figure 58: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2018 & 2026
Figure 59: Middle East & Africa Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2018
Figure 60: Global Cancer Biomarkers Market Share (%), By Company, 2018
Browse more info on this Report @ https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630
About Us
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand current competitive challenges.
Author’s Bio
Name- Raginee Sarkar
Raginee currently works as a content writer at Fortune Business Insights™. She comes with extensive experience in writing advertising and marketing content, blogging, film scripting, and news reporting. She strongly believes in quality content and thus prefers to write in a simple, elegant, yet impactful way.